Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
about
Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertensionStructure-activity relationship studies of the tricyclic indoline resistance-modifying agent.Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics.Endothelin receptor A antagonism attenuates renal medullary blood flow impairment in endotoxemic pigs.The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?Vasoactive peptides in cardiovascular (patho)physiology.Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.Leads for the treatment of pulmonary hypertension.A facile and convenient synthesis of some novel hydrazones, Schiff's base and pyrazoles incorporating thieno[2,3-b]thiophenesBosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.DBU-mediated [4 + 1] annulations of donor-acceptor cyclopropanes with carbon disulfide or thiourea for synthesis of 2-aminothiophene-3-carboxylates.
P2860
Q21284417-72F1FD14-69B8-446F-B71C-3F11D3F8BA46Q33598767-6F6CF026-FCBC-4CFA-B9C0-B20A072F04FEQ33684443-FB3A17BD-6B6F-4C46-9265-63CED03F199CQ33961467-91AFA63B-0775-4BDD-807F-07A8B40ECD34Q36510011-2FA477EC-E3AF-4844-B230-5E21E83CEC2DQ36815987-239E1F0E-A9B4-459D-A816-E0DE207F3CA8Q37019838-A961F66C-51B2-48FA-BF53-E447BE6C4E76Q37481343-97769824-A4F9-4D48-AD21-DC20CF498BACQ39675429-D3A780F1-0FAD-48FA-B5B1-60BA59463621Q39941690-754107CE-51C5-4585-AA42-8466A7B111F4Q47691128-90A9CD0C-DAB7-40BB-998F-0A48F0FB45B4
P2860
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Discovery, modeling, and human ...... ailable endothelin antagonist.
@en
Discovery, modeling, and human ...... ailable endothelin antagonist.
@nl
type
label
Discovery, modeling, and human ...... ailable endothelin antagonist.
@en
Discovery, modeling, and human ...... ailable endothelin antagonist.
@nl
prefLabel
Discovery, modeling, and human ...... ailable endothelin antagonist.
@en
Discovery, modeling, and human ...... ailable endothelin antagonist.
@nl
P2093
P356
P1476
Discovery, modeling, and human ...... ailable endothelin antagonist.
@en
P2093
Andree R Bourgoyne
Chengde Wu
E Radford Decker
George W Holland
Kurt L Berens
Natalie Blok
Richard A F Dixon
Tommy A Brock
Tony J You
P304
P356
10.1021/JM030528P
P407
P50
P577
2004-04-01T00:00:00Z